Download full-text PDF |
Source |
---|
PLoS One
January 2025
Laboratory for Microbiome Sciences, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Biliary stent occlusion is due, in part, to biofilm formation by bacteria. However, previous culture-based approaches may not have revealed all microorganisms on the surface. Twenty-seven patients underwent endoscopic retrograde biliary drainage for the removal or replacement of plastic biliary stents.
View Article and Find Full Text PDFJ Vasc Surg Cases Innov Tech
February 2025
Department of Vascular Surgery, National Institute of Cardiology Ignacio Chávez, Mexico City, Mexico.
Zhonghua Yu Fang Yi Xue Za Zhi
December 2024
Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing100020, China.
This study aimed to analyze the clinical characteristics and prognosis of Takayasu's arteritis (TA) with carotid artery occlusion in children. This study collected clinical data and follow-up information on the first diagnosis and treatment of c-TA combined with carotid artery occlusion in pediatric patients at the Children's Hospital affiliated with the Capital Institute of Pediatrics and Inner Mongolia Medical University Affiliated Hospital from 2013 to 2023. This study included four female patients with a mean age of (13.
View Article and Find Full Text PDFMedicine (Baltimore)
December 2024
Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Rationale: Takayasu arteritis (TAK) is an autoimmune disease that causes chronic inflammation targeting the aortic wall. Since many patients are resistant to steroid treatment, multiple immunosuppressants or interleukin-6 (IL-6) suppression therapy have served as treatment alternatives. However, there are very few reports on the effectiveness of biologics against inflammatory cytokines upstream of IL-6.
View Article and Find Full Text PDFCancer Med
December 2024
Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.
Introduction: Extensive small cell lung cancer (ES-SCLC) are currently managed using first-line chemotherapy options, including atezolizumab (Atezo) plus etoposide and carboplatin (CE) or durvalumab (Durva) plus etoposide with either cisplatin (PE) or carboplatin (CE). However, a definitive distinction in therapeutic effects between Atezo and Durva in these regimens remains unestablished.
Methods: We analyzed data from 100 patients diagnosed with ES-SCLC who received immune checkpoint inhibitors (ICIs) as first-line chemotherapy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!